AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration.
AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration. When combined with the reduction in R&D headcount of 1600 announced earlier this week, and the elimination of 1150 positions related to restructuring of a Phase III workforce announced in February 2012, the new announcement brings the total headcount reduction to approximately 5050 over the 2013–2016 period.
In a press release, the company outlined five areas of focus intended to return the company to growth. The company will focus on capturing market share for its platelet aggregation inhibitor, Brilanta (ticagrelor); partner with Bristol Myers-Squibb to achieve a leading position in the noninsulin diabetes market; invest in emerging markets, particularly China; invest in its on-market respiratory portfolio and accelerate its pipeline of respiratory projects; and capture the potential from its established brands and new launches in Japan.
According to the release, the combined program of changes is estimated to incur $2.3 billion in one-time restructuring charges, of which $1.7 billion are expected to be cash costs. Benefits of approximately $800 million per year are expected by 2016.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.